ABN 16 165 160 841

ASX RELEASE **11 January 2023**

Dose Escalation Approved in ACCENT Clinical Trial of AMP945

HIGHLIGHTS

- The ACCENT clinical trial assessing the efficacy of AMP945 in treating pancreatic cancer patients has now been approved for dose escalation and recruitment of planned second patient cohort.
- The Safety Review Committee has examined the available safety, pharmacokinetic and pharmacodynamic data and concluded that dose escalation to a further cohort is warranted.

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to advise that following a review of safety data collected to date, the ACCENT clinical trial's Safety Review Committee has approved dose escalation of AMP945 and recruitment of another patient cohort.

The first stage of the ACCENT trial is designed to identify the most suitable dose of AMP945 to combine with gemcitabine/nab-paclitaxel chemotherapy in patients with advanced pancreatic cancer. Accordingly, ascending doses of AMP945 are given in combination with standard gemcitabine/nab-paclitaxel chemotherapy while safety, pharmacokinetics and pharmacodynamics are monitored. Dose escalation of AMP945 will continue until either a dose-limiting safety signal is identified or the pharmacodynamic effect of AMP945 reaches a plateau. The Company expects that up to four cohorts of three patients may be required to identify the most suitable dose of AMP945.

Following completion of recruitment of the first cohort in late 2022, drug safety and tolerability was monitored for a minimum of one treatment cycle (28 days). The ACCENT trial's Safety Review Committee has now examined the available safety, pharmacokinetic and pharmacodynamic data and concluded that dose escalation to a further cohort is warranted.

Amplia's CEO and Managing Director Dr Chris Burns commented: *"We are delighted that the data we have collected for AMP945, when used in combination with gemcitabine and nab-paclitaxel, supports dose escalation in the second cohort of patients. The performance of AMP945 appears to be tracking well, and is aligned with our expectations based on the excellent profile AMP945 demonstrated in the previous Phase 1 clinical trial in healthy volunteers."*

This ASX announcement has been approved and authorised for release by the Board of Amplia Therapeutics.

- End -

For Further Information

Dr Chris Burns

CEO and Managing Director

chris@ampliatx.com

www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).